Last reviewed · How we verify
Multiple Ascending Doses of EB8018 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Multiple Ascending Doses of EB8018 (Multiple Ascending Doses of EB8018) — Enterome.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Multiple Ascending Doses of EB8018 TARGET | Multiple Ascending Doses of EB8018 | Enterome | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Multiple Ascending Doses of EB8018 CI watch — RSS
- Multiple Ascending Doses of EB8018 CI watch — Atom
- Multiple Ascending Doses of EB8018 CI watch — JSON
- Multiple Ascending Doses of EB8018 alone — RSS
Cite this brief
Drug Landscape (2026). Multiple Ascending Doses of EB8018 — Competitive Intelligence Brief. https://druglandscape.com/ci/multiple-ascending-doses-of-eb8018. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab